The publication of this infographic was funded by Boehringer Ingelheim. This content is intended for US Healthcare Professionals.
Disclaimer: Zongertinib is a tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 (ERBB2). This orally administered, targeted therapy was approved as HERNEXEOS® (zongertinib tablets) under the FDA’s Accelerated Approval Program, after securing Priority Review as well as Breakthrough Therapy and Fast Track Designations. Please see full for HERNEXEOS.
In HER2 (ERBB2)-mutant NSCLC, brain metastases present a significant unmet need. Read this infographic to explore the intracranial activity of zongertinib and its systemic efficacy and safety in patients with and without brain metastases at baseline.
Uncover:
- How common are brain metastases in HER2-mutant NSCLC?
- Does zongertinib provide intracranial response without prior brain radiotherapy?
- How consistent is systemic activity in patients with and without brain metastases?
- What does the safety profile look like in patients with stable, asymptomatic brain metastases?
